|Awarded On||August 19, 2020|
|Title||Novel Betabody-Drug Conjugates Targeting Phosphatidylserine for the Selective Delivery of Potent, Small-Molecule Payloads|
|Award Mechanism||High Impact/High Risk|
|Principal Investigator/Program Director||Kevin G Pinney|
|Cancer Sites||Breast, Lung and Bronchus, Pancreas|
*Pending contract negotiation
This proposal advances the first-in-class synthesis and biological evaluation of protein-drug conjugates that feature engineered proteins (called betabodies) that target the lipid phosphatidylserine (PS). PS is in the inside part (inner leaflet) of the membrane that surrounds normal cells, but in cancer cells and cells lining tumor blood vessels, PS is flipped and exposed on the outside of the cell. In addition, PS exposed on cancer cells helps to suppress the immune response that fights cancer. Specific protein antibodies that attach to PS have demonstrated the ability to delay tumor growth in multiple mouse models of cancer. Betabodies also bind to PS, but since they are smaller than antib...